Lung Toxicity Induced by Anti-HER2 Antibody- Drug Conjugates for Breast Cancer
-
Published:2024-01
Issue:
Volume:
Page:104274
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Chai Mengting, Li Li, Wu Huachao, Liu Yue, Yi Zongbi, Yu HaijunORCID
Subject
Oncology,Hematology
Reference60 articles.
1. HER-2 Positive Breast Cancer - a Mini-Review;Asif;Asian Pacific Journal of Cancer Prevention,2016 2. Antibody drug conjugate: the “biological missile” for targeted cancer therapy;Fu;Signal Transduction and Targeted Therapy,2022 3. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer;Verma;New England Journal of Medicine,2012 4. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer;Modi;New England Journal of Medicine,2020 5. Wang J.W., Jiayu); Liu, Y.J. (Liu, Yunjiang); Zhang, Q.Y. (Zhang, Qingyuan); Feng, J.F. (Feng, Jifeng); Fang, J.M. (Fang, Jianmin); Chen, X.L. (Chen, Xuelian); Han, Y.Q. (Han, Yiqun); Li, Q. (Li, Qing); Zhang, P. (Zhang, Pin); Yuan, P. (Yuan, Peng); Ma, F. (Ma, Fei); Luo, Y. (Luo, Yang); Fan, Y. (Fan, Ying); Cai, R.G. (Cai, Ruigang); Chen, S.S. (Chen, Shanshan); Li, Q. (Li, Qiao); Li, Y.Q. (Li, Yiqun); Xu, B.H. (Xu, Binghe). RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. Journal of Clinical Ocology. 2021;39(15).
|
|